Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.
RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.
A user is experiencing severe dandruff and hair loss, considering using ketoconazole shampoo 2% to manage these issues. They seek advice on application frequency and effectiveness, with suggestions to use it 2-3 times a week and to consider other treatments like finasteride for hair loss.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
The user experiences immediate hair shedding linked to stress, unlike typical telogen effluvium, and is seeking answers. A suggestion was made to use spironolactone and topical minoxidil to address potential DHT-related shedding.
To minimize hair loss while using steroids, use finasteride or dutasteride and apply topical anti-androgens like RU58841. Avoid high doses of hair-toxic steroids; prefer testosterone, nandrolone, and boldenone.
Topical estrogen or estradiol for hair loss is being discussed for its effectiveness compared to finasteride. Users are sharing their experiences and opinions on its potential benefits.
A user has been using 5% minoxidil and a derma pen for one month, experiencing shedding but noticing potential new hair growth. They plan to add finasteride to their regimen.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user gained 10-12 kg after starting finasteride but found their estrogen levels to be within the normal range. They are concerned about potential gynecomastia but are reassured by their lab results.
A user regrew all their hair, including temples and bald spots, after one year of finasteride and six months of oral minoxidil. They noted finasteride helped with the crown and bald spot, while minoxidil regrew the hairline and temples.
A 23-year-old male was using 0.5 mg of dutasteride daily, 10% minoxidil twice daily for 4-5 months then once daily, and vitamin D for a month for hair loss treatment but saw a decline in results. It's suggested that the decline may be due to reducing minoxidil application to once a day and a doctor's visit is recommended for further advice.
The conversation discusses natural DHT blockers like rice bran oil, which may reduce 5α-reductase activity similarly to Minoxidil and Dutasteride. One user argues that finasteride is more reliable and effective than natural alternatives.
The conversation is about an 18-month hair loss treatment with Minoxidil 5% used twice daily and Finasteride 1 mg taken every day, showing significant progress. Participants discuss the form of Minoxidil used, side effects like dandruff, the time taken to see results, and encouragement from the visible improvement.
The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.
An 18-year-old male experiencing hair thinning and loss is using oral minoxidil, topical minoxidil, finasteride, and a multivitamin as prescribed by a dermatologist. He's having difficulty applying the topical minoxidil effectively due to his hair length, as he feels a lot of it stays on his hair instead of reaching the scalp.
A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.
The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.
Hair loss treatment using Hims 2 in 1 Minoxidil/Finasteride Spray and dermarolling twice a week for 3 months. One user considers adding topical Finasteride to their oral Finasteride regimen.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.
A three-month progress report of using Dutasteride, oral Minoxidil, Ketoconazole shampoo, RU58841 and Dermarolling to combat hair loss. The results have been encouraging so far.
Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.
The conversation is about individuals considering waiting for Breezula to treat hair loss instead of using Finasteride due to concerns about side effects. Some are opting for Finasteride now, while others are wary of its impact on neurosteroids.
The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.
A user's 2-year experience with Minoxidil and Finasteride as a treatment for hair loss, including the costs involved and potential side effects. Other users shared their experiences and asked questions about their own use of these treatments.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.